BTTC Trials Presented at the 2015 ASCO Meeting

The American Society of Clinical Oncology held their annual meeting from May 29 - June 2, 2015 in Chicago, Illinois. This meeting brings together 30,000 oncology professionals from around the world.

BTTC investigators presented results from two BTTC clinical trials during the poster presentations. A brief synopsis of their key findings is provided below.

Dr. Vinay Puduvalli of Ohio State University Comprehensive Cancer Center and Wexner Medical Center, shared the results from the BTTC 11-02, Adaptive Randomized Phase II Trial of Bevacizumab Plus Vorinostat Versus Bevacizumab Alone in Adults with Recurrent Glioblastoma.

The trial aimed to test the idea that a novel drug, vorinostat, could overcome resistance that brain tumors develop to drugs like bevacizumab that block blood vessel growth in these tumors. While the study results did not show a difference in when the new drug was added to bevacizumab, this study used for the first time in our field, a novel trial design (called a Bayesian adaptive design) in a multicenter setting made possible by the active participation and collaboration of the BTTC institutions that could pave the way for future trials using this design. This has the potential to more efficiently and accurately test drugs to find the most active ones.

View ASCO’s online poster.

Dr. Jeffrey Raizer of Northwestern University, presented results from the BTTC 09-01 study, Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas.

This trial was designed to target two pathways involved in glioma progression.  The phase I data were presented and showed that a tolerable dose could be achieved. This dose is currently being used in a phase II trial that is nearing completion.

View ASCO’s online poster.